GSK Makes $750 Million Settlement Over Manufacturing Investigation

GlaxoSmithKline (GSK) and the Justice Department have finalized a settlement agreement in which the UK drugmaker will pay $750 million to settle an investigation into a now-shuttered Puerto Rico facility where adulterated drugs were made.

According to a government investigation, GSK subsidiary SB Pharmco manufactured drugs at the Cidra, Puerto Rico, factory that were not mixed correctly, leading them to be ineffective, and put drugs in the wrong packaging and bottles.

GSK said the facility was closed in 2009 for business reasons, but the company worked hard to resolve the manufacturing issues before the closure.
Drug GMP Report